Page 233 - Read Online

Zhang et al. J Cancer Metastasis Treat 2020;6:21 I http://dx.doi.org/10.20517/2394-4722.2020.40 Page 11 of 11

58. Chattopadhyay S, Thomsen H, Yadav P, da Silva Filho MI, Weinhold N, et al. Genome-wide interaction and pathway-based identification
of key regulators in multiple myeloma. Commun Biol 2019;2:89.
59. Walker BA, Wardell CP, Brioli A, Boyle E, Kaiser MF, et al. Translocations at 8q24 juxtapose MYC with genes that harbor
superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J 2014;4:e191.
60. Li ZR, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, et al. A global transcriptional regulatory role for c-Myc in Burkitt’s lymphoma
cells. Proc Natl Acad Sci USA 2003;100:8164-9.
61. Mathsyaraja H, Freie B, Cheng PF, Babaeva E, Catchpole JT, et al. Max deletion destabilizes MYC protein and abrogates Emicro-Myc
lymphomagenesis. Genes Dev 2019;33:1252-64.
62. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, et al. Selective inhibition of BET bromodomains. Nature 2010;468:1067-73.
63. Balasubramanian S, Hurley LH, Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug
Discov 2011;10:261-75.
64. Wang KB, Elsayed MSA, Wu G, Deng N, Cushman M, et al. Indenoisoquinoline topoisomerase inhibitors strongly bind and stabilize the
MYC promoter G-quadruplex and downregulate MYC. J Am Chem Soc 2019;141:11059-70.